# OnCo record pylarify (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pylarify/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pylarify" ;
  schema:name "Piflufolastat F-18 / Pylarify TruVu"@en ;
  schema:alternateName "Piflufolastat (18F)"@en, "Pylclari"@en, "Pylarify" ;
  schema:description "Piflufolastat F-18 (Pylarify) is the leading PSMA PET tracer for prostate cancer, with a new formulation approved in March 2026."@en ;
  schema:url <https://onco.cc/drugs/pylarify/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Piflufolastat_F-18> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Piflufolastat%20F-18> ;
  onco:status "approved" ;
  onco:modality "PET imaging agent" ;
  onco:approval "US 2021: PSMA PET imaging in prostate cancer", "US 2026: Pylarify TruVu formulation", "EU 2023: EU brand Pylclari (Curium)" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/psma-pet/> ;
  onco:targets <https://onco.cc/targets/psma/> ;
  onco:companies <https://onco.cc/companies/lantheus/> ;
  onco:trials <https://onco.cc/trials/nct03739684/>, <https://onco.cc/trials/nct04457245/>, <https://onco.cc/trials/nct02981368/> .